Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$10.20 +3.7%	$8.19	$3.76 ▼ $46.80	$62.74M	2.77	63,314 shs	112,747 shs
IBIO iBio	$0.79 +1.9%	$0.73	$0.56 ▼ $6.89	$15.26M	0.6	1.39 million shs	411,981 shs
IPSC Century Therapeutics	$0.54 +0.0%	$0.57	$0.34 ▼ $2.05	$46.75M	1.78	887,867 shs	1.03 million shs
STTK Shattuck Labs	$0.96 +7.3%	$0.86	$0.69 ▼ $3.95	$45.99M	1.63	5.25 million shs	489,082 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	0.00%	+32.47%	+14.48%	+85.45%	-25.82%
IBIO iBio	0.00%	+6.72%	+6.95%	-3.30%	-61.03%
IPSC Century Therapeutics	0.00%	-3.67%	-17.96%	-3.15%	-69.77%
STTK Shattuck Labs	0.00%	-4.00%	+10.46%	-11.11%	-72.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALGS Aligos Therapeutics	4.5537 of 5 stars	3.5	4.0	4.8	3.4	1.7	0.6
IBIO iBio	1.8649 of 5 stars	3.5	0.0	0.0	2.5	0.0	0.6
IPSC Century Therapeutics	3.0179 of 5 stars	3.5	4.0	0.0	2.3	1.7	0.6
STTK Shattuck Labs	3.5104 of 5 stars	3.4	5.0	0.0	2.4	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALGS Aligos Therapeutics	3.00	Buy	$50.00	390.20% Upside
IBIO iBio	3.00	Buy	$5.00	532.11% Upside
IPSC Century Therapeutics	3.00	Buy	$3.75	592.90% Upside
STTK Shattuck Labs	2.83	Moderate Buy	$7.00	629.17% Upside

Current Analyst Ratings Breakdown

Latest IBIO, IPSC, STTK, and ALGS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ALGS Aligos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
8/14/2025	STTK Shattuck Labs	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$4.00 ➝ $2.00
8/14/2025	STTK Shattuck Labs	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/25/2025	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALGS Aligos Therapeutics	$3.94M	15.92	N/A	N/A	$16.56 per share	0.62
IBIO iBio	$375K	41.46	N/A	N/A	$1.41 per share	0.56
IPSC Century Therapeutics	$6.59M	7.09	N/A	N/A	$2.43 per share	0.22
STTK Shattuck Labs	$5.72M	8.04	N/A	N/A	$1.19 per share	0.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALGS Aligos Therapeutics	-$131.21M	-$19.79	N/A	N/A	N/A	-2,337.24%	-22.41%	-12.09%	11/5/2025 (Estimated)
IBIO iBio	-$24.91M	N/A	0.00	N/A	N/A	N/A	-73.15%	-45.51%	N/A
IPSC Century Therapeutics	-$126.57M	-$0.29	N/A	N/A	N/A	-19.10%	-11.53%	-6.94%	11/4/2025 (Estimated)
STTK Shattuck Labs	-$75.41M	-$1.21	N/A	N/A	N/A	N/A	-81.80%	-71.46%	N/A

Latest IBIO, IPSC, STTK, and ALGS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	IPSC Century Therapeutics	-$0.38	-$0.38	N/A	-$0.38	$0.03 million	N/A
8/14/2025	Q2 2025	STTK Shattuck Labs	-$0.25	-$0.24	+$0.01	-$0.24	N/A	N/A
8/6/2025	Q2 2025	ALGS Aligos Therapeutics	-$2.35	-$1.53	+$0.82	-$1.53	$0.43 million	$0.97 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALGS Aligos Therapeutics	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A
IPSC Century Therapeutics	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALGS Aligos Therapeutics	N/A	6.31	6.31
IBIO iBio	0.05	1.76	1.76
IPSC Century Therapeutics	N/A	10.72	11.70
STTK Shattuck Labs	N/A	10.25	9.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALGS Aligos Therapeutics	60.43%
IBIO iBio	7.90%
IPSC Century Therapeutics	50.20%
STTK Shattuck Labs	58.74%

Insider Ownership

Company	Insider Ownership
ALGS Aligos Therapeutics	4.80%
IBIO iBio	0.58%
IPSC Century Therapeutics	5.00%
STTK Shattuck Labs	12.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALGS Aligos Therapeutics	90	6.15 million	5.86 million	No Data
IBIO iBio	100	19.66 million	9.82 million	N/A
IPSC Century Therapeutics	170	86.39 million	82.07 million	Optionable
STTK Shattuck Labs	100	47.90 million	42.16 million	Optionable

IBIO, IPSC, STTK, and ALGS Headlines

Recent News About These Companies

Shattuck Labs, Inc.: Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

August 22 at 10:45 AM | finanznachrichten.de

Shattuck Labs says IND for SL-325 for treatment of IBD in effect

August 22 at 10:45 AM | msn.com

Shattuck Labs Reports Q2 2025 Financial Results

August 22 at 10:45 AM | msn.com

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

August 21 at 10:17 AM | globenewswire.com

Shattuck Labs raises up to $103M to fund therapeutic antibody development

August 19, 2025 | ncbiotech.orgN

Shattuck Labs, Inc. (NASDAQ:STTK) Given Average Recommendation of "Moderate Buy" by Brokerages

August 19, 2025 | americanbankingnews.com

Leerink Partnrs Estimates Shattuck Labs Q1 Earnings

August 18, 2025 | americanbankingnews.com

Shattuck Labs' (STTK) "Hold" Rating Reiterated at Needham & Company LLC

August 17, 2025 | americanbankingnews.com

Shattuck Labs (NASDAQ:STTK) Price Target Lowered to $2.00 at Leerink Partners

August 16, 2025 | americanbankingnews.com

Shattuck Labs price target lowered to $2 from $4 at Leerink

August 14, 2025 | msn.com

Shattuck Labs Submits IND Application for SL-325; Phase 1 Trial in Healthy Volunteers Expected to Begin Q3 2025

August 14, 2025 | quiverquant.comQ

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 14, 2025 | globenewswire.com

Shattuck Labs expects $103 million from private placing

August 6, 2025 | thepharmaletter.comT

Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

August 5, 2025 | globenewswire.com

Shattuck Labs Elects Directors, Approves Auditor at Meeting

July 15, 2025 | tipranks.com

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

July 2, 2025 | globenewswire.com

Shattuck Labs, Inc. (STTK) - Yahoo Finance

June 28, 2025 | finance.yahoo.com

Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

June 13, 2025 | finance.yahoo.com

Shattuck Labs Advances SL-325 Program Amid Financial Progress

May 5, 2025 | tipranks.com

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO, IPSC, STTK, and ALGS Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

$10.20 +0.36 (+3.66%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$9.93 -0.27 (-2.70%)

As of 08/22/2025 04:38 PM Eastern

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

iBio NYSE:IBIO

$0.79 +0.01 (+1.89%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.78 -0.01 (-1.01%)

As of 08/22/2025 07:50 PM Eastern

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

Century Therapeutics NASDAQ:IPSC

$0.54 +0.00 (+0.02%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.55 +0.00 (+0.70%)

As of 08/22/2025 07:57 PM Eastern

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Shattuck Labs NASDAQ:STTK

$0.96 +0.07 (+7.30%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.94 -0.02 (-2.08%)

As of 08/22/2025 06:17 PM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time